Sign inJoin waitlistJoin the waitlist

Sara Tolaney

Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers · Mass General Brigham

Credentials: · · · ·

History

Division of Breast Oncology · Mass General Brigham
Present
the Division · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2005–2008
Internal Medicine
Johns Hopkins Hospital
2002–2005
Harvard School of Public Health
University of California, San Francisco School of Medicine
1998–2002
Princeton University
1994–1998

Research

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Annals of Oncology · 2021 · 1,195 citations
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2018 · Last of 7 authors · 880 citations

Eric Winer
110 papers
Nancy Lin
106 papers
PT
Paolo Tarantino
73 papers
Elizabeth Mittendorf
70 papers
Hope Rugo
67 papers
IK
Ian Krop
61 papers
Ann Partridge
46 papers
Adrienne Waks
40 papers · 3 as a fellow
Ana Garrido-Castro
35 papers · 11 as a resident
Aditya Bardia
34 papers
Filipa Lynce
30 papers
Harold Burstein
30 papers

Grants

Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $149.4K · Dana-Farber Cancer Inst
1997–2026

Clinical trials

ATEMPT 2.0: Adjuvant T-DM1 vs TH
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
2021–2029
Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Principal investigator · Active not recruiting
Dana-Farber Cancer Institute
2019–2026
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2019–2027
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2018–2026